Truist Financial’s ProQR Therapeutics PRQR Stock Holding History

Truist Financial’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.6K	Hold	10,000	–	–	﹤0.01%	2887
2026 Q2	$18.6K	Hold	10,000	–	–	﹤0.01%	2905
2026 Q1	$16.2K	Hold	10,000	–	–	﹤0.01%	2780
2025 Q4	$20.2K	Hold	10,000	–	–	﹤0.01%	2747
2025 Q3	$21.3K	Hold	10,000	–	–	﹤0.01%	2701
2025 Q2	$20.4K	Hold	10,000	–	–	﹤0.01%	2578
2025 Q1	$13.3K	Hold	10,000	–	–	﹤0.01%	2531
2024 Q4	$26.5K	Hold	10,000	–	–	﹤0.01%	2495
2024 Q3	$18.2K	Hold	10,000	–	–	﹤0.01%	2472
2024 Q2	$16.6K	Hold	10,000	–	–	﹤0.01%	2626
2024 Q1	$22.9K	Hold	10,000	–	–	﹤0.01%	2598
2023 Q4	$19.8K	Hold	10,000	–	–	﹤0.01%	2614
2023 Q3	$13K	Hold	10,000	–	–	﹤0.01%	2570
2023 Q2	$16.2K	Buy	+10,000	New	+$19.5K	﹤0.01%	2548

Other funds holding PRQR

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Monaco Asset Management Monaco $818M AUM 32.61% 1-Year Est. Return

M28 Capital Management Stamford, Connecticut $36M AUM 11.62% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Truist Financial's PRQR Position: Q3 2026 in Review

Truist Financial held its ProQR Therapeutics (PRQR) position steady in Q3 2026 at 10,000 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2887.

Truist Financial first reported a position in PRQR in Q2 2023 and has held it in 14 quarters since. The position peaked at $26.5K in Q4 2024. 42 funds tracked by Wall St. Rank hold PRQR as of Q3 2026.

Truist Financial held 10,000 shares of ProQR Therapeutics worth $16.6K as of Q3 2026.
Truist Financial left its ProQR Therapeutics share count unchanged in Q3 2026.
ProQR Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q3 2026, its #2887 holding.
Truist Financial first reported a position in ProQR Therapeutics in Q2 2023 and has held it in 14 quarters since.
Truist Financial's ProQR Therapeutics position peaked at $26.5K in Q4 2024.
42 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2026.

Based on Truist Financial's 13F filing for Q3 2026, filed 30 Oct 2026.